(This measure has not been amended since it was introduced. The summary of that version is repeated here.)
Expresses the sense of the Senate that the Centers for Medicare & Medicaid Services should: (1) begin an immediate reconsideration of the final National Coverage Determination on the Use of Erythropoiesis Stimulating Agents in Cancer and Related Neoplastic Conditions (CAG-000383N); (2) consult with members of the clinical oncology community to determine appropriate revisions to it: and (3) implement such revisions as soon as feasible, and brief Congress in advance of announcing such changes.
Introduced in Senate
Referred to the Committee on Finance. (text of measure as introduced: CR S10943-10944)
Senate Committee on Finance discharged by Unanimous Consent.(consideration: CR S11080-11081)
Senate Committee on Finance discharged by Unanimous Consent. (consideration: CR S11080-11081)
Passed/agreed to in Senate: Resolution agreed to in Senate without amendment and with a preamble by Unanimous Consent.(text: CR S11080-11081)
Resolution agreed to in Senate without amendment and with a preamble by Unanimous Consent. (text: CR S11080-11081)
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line